Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. - Wikidata - wikimedia - TriplyDB

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.

http://www.wikidata.org/entity/Q39093621

about

Use of miRNAs as biomarkers in sepsis CGAT: a model for immersive personalized training in computational genomics.Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus.Genotyping the High Altitude Mestizo Ecuadorian Population Affected with Prostate Cancer PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway.A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Network analysis of an in vitro model of androgen-resistance in prostate cancer.Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.SOX4 Is Essential for Prostate Tumorigenesis Initiated by PTEN Ablation.The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer Investigation of the molecular mechanisms underlying metastasis in prostate cancer by gene expression profiling c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway.Tankyrases: structure, function and therapeutic implications in cancer.Wnt signaling in castration-resistant prostate cancer: implications for therapy.The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration.Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.Drug discovery in advanced prostate cancer: translating biology into therapy.Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth.CGAT: computational genomics analysis toolkit.RNA-Seq-Based Transcriptome Analysis of Changes in Gene Expression Linked to Human Pregnancy Outcome After In Vitro Fertilization-Embryo Transfer.The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells.Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.WNT signalling in prostate cancer.Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.The Genomics of Prostate Cancer: emerging understanding with technologic advances.Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation

P2860

Q26801909-BB633E21-914F-47D9-A5A4-DE261828268E Q27691457-09D91893-0B10-4D63-93FD-DA8CB35C8999 Q28829206-EAE5B529-7139-43C3-8B10-7302EED12A99 Q30300669-DB481D63-755C-4BCD-AFEE-10944F8A199E Q33823048-F53DE536-3D0B-42DC-9B3B-7EBB91167358 Q33827484-6E1F8C96-542C-46ED-9658-57DC09719EF1 Q34550256-B3C1F9F2-2FB1-415C-BA6C-80DABB453389 Q34993890-9AD36A68-FDBF-4803-879F-3311485DF6B1 Q35555483-217ADA07-4FA0-41C3-8EDC-3A56C5B9B672 Q35836735-CB5C8579-30B9-4294-8165-B71434BACEAD Q36637412-445DF810-DEA1-4289-AB59-E63E8B6592EB Q36655495-E0193BD8-97EF-4CE5-9461-A35B1E5256F4 Q37051378-69DD6516-3953-44BD-ADA7-7F09F3392558 Q37108412-964D6FF8-6A50-4646-9E3E-6D54F8DF1B04 Q37688990-E0F9318D-6E02-4D71-9317-7EDFE47D5157 Q37739979-76A63349-1FAE-4E62-B91F-EEF526753F6A Q38224266-A6A94999-5930-4FD9-9136-9925C0046C46 Q38241850-32F75872-9E05-4FD4-BC91-B3EB74781456 Q38259961-2AB1F534-47FD-4E6B-8227-B5DD6FD81B8B Q38643148-B40C2D9A-BA5D-45EF-B2B0-8F116B2075A2 Q38681961-C64692FC-61FA-4DB1-A261-EC83E19D845F Q38757500-5164DD82-073A-4013-8C7D-EAB12B60B2CC Q38770371-ABC25275-1131-4D51-A47D-82CD056CEAFE Q38839110-4E1AF868-47A1-41C8-90E6-4A3888EBA9BC Q38884390-4B661231-3940-4CB2-BD2A-95E57F87668F Q38940368-0B6611E2-87D7-49EF-9BE8-BBEE928934FC Q38976894-29D0BC75-E5B3-4411-8CD1-30F65F4A0543 Q40393450-9DE393E8-CF27-47C5-AEB0-01F9764D4CB9 Q40656134-23E4F4AA-ED4C-4AE1-92D3-423267DCEAC5 Q47100267-16C21D7C-3954-46C3-B7CD-2297A9763880 Q47140347-9B54BE12-050D-4B70-9D78-D565DA4909BC Q47406034-399E38CF-5516-4BBD-96A7-F88711D93509 Q47818549-EC7B7D9C-420F-4D6F-927F-0690FB8C8792 Q48040556-6F772467-77B6-4897-85C2-DC00004BFC10 Q48317607-698F2F54-16C9-44FB-BAA7-CA5E8727CF9D Q51019461-784BB0D8-72E6-40AA-9239-2532D4455C6B Q52615484-6CFCB928-E707-4E99-B1F7-5186BD5F7109 Q57106289-DDBCFBDC-5D53-4405-8C53-A8059FA94C4A Q58777826-AC2F5E50-E551-4DA0-A12F-1467236A25B8

P2860

Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.

http://www.wikidata.org/entity/Q39093621

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Next-generation sequencing of ...... androgen-deprivation therapy.

@en

Next-generation sequencing of ...... androgen-deprivation therapy.

@nl

type

label

Next-generation sequencing of ...... androgen-deprivation therapy.

@en

Next-generation sequencing of ...... androgen-deprivation therapy.

@nl

prefLabel

Next-generation sequencing of ...... androgen-deprivation therapy.

@en

Next-generation sequencing of ...... androgen-deprivation therapy.

@nl

P1433

Q39093621-AE384E27-F780-407A-ACFE-E8AF16945C20

P1476

Q39093621-CF8D3DA3-19DB-43BF-A48F-D9E9350F9BD7

P2093

Q39093621-7319A5B3-D0DE-44BC-92E3-91819D9110DB

Q39093621-8CE2D367-4B6F-4A47-99CB-D0B5235506E0

Q39093621-A83737B6-7C9D-484B-9EAC-9B644F228ECE

Q39093621-C362718C-6CE3-4026-B3BC-CDE92BF6A16A

Q39093621-DFC1F3D0-FC9B-4605-A7B5-06760099CD72

Q39093621-F00FAE75-0E96-47C1-A176-9360FE3ADC49

Q39093621-FDC4AA60-76EC-431D-8741-B011352B7D42

P2860

Q39093621-01AED7D1-296C-4471-BDC8-ADD4B5923A6F

Q39093621-07EE9F1D-D415-4DEE-B6C6-8957BDF7932B

Q39093621-1317C3FB-2CE2-4619-8EE2-CC06B1AD7065

Q39093621-183B4811-E292-41B6-AB1D-1FE797E0ED4E

Q39093621-195AB4DF-F85F-4695-A27E-8D8C9D4C3FEF

Q39093621-26B0C385-0476-45FB-B6FA-B4FA701022B4

Q39093621-2E295529-9A98-45F4-B30B-A3CDEAE6152D

Q39093621-30223AB3-846F-45E3-9705-5ADEC511C827

Q39093621-306A9DCF-6371-4F85-BFE8-594B84750827

Q39093621-33E7209C-6E51-46AA-8483-BE04205A06DF

P304

Q39093621-DA211595-5532-4E29-A39B-0BF9F9EDB9DA

P31

Q39093621-82F72BB6-F651-494F-B69E-192F56BA93A1

P356

Q39093621-9EE9EB6E-836D-4CDC-8777-AF90E4376B76

P407

Q39093621-7820F235-071D-4C74-BDDB-A0C4B76C195F

P433

Q39093621-13AD8354-F665-43FF-916A-82DC657A53B3

P478

Q39093621-1532EADE-2B7C-4A86-B528-EDF4F2E821B3

P50

Q39093621-11B92A3C-D103-4600-819A-2F2E85A4D2DA

Q39093621-17FA0026-E914-486C-94A3-D5C6AB6A556A

Q39093621-66FCBBF9-B47B-431C-A7B0-6D6A1D5D5683

Q39093621-7FE558E8-8331-4BE5-B9CC-73EFE541FFF9

Q39093621-860EB4B7-D1E5-4513-9951-5963E5ED746D

Q39093621-910E9925-D865-47FB-BCE1-B161DDC1E8F9

Q39093621-B16D94B5-9A8E-4F32-9015-5BD6D9898F77

Q39093621-BC91FD65-9A03-491C-9A78-0137DE028134

P577

Q39093621-124924B3-DE27-4CF8-BD66-54B220A1314D

P5875

Q39093621-4AD4DE5F-AF87-4F50-95BD-BC01259101EE

P698

Q39093621-E4D67900-7837-4001-BFE4-0596926BD01F

P921

Q39093621-05861EBB-50E8-4131-AE43-7A5F74F3DB0C

P932

Q39093621-282A9168-7728-49A3-8B6B-F6B946D4AC4B

P356

J.EURURO.2013.08.011

P1433

European Urology

P1476

Next-generation sequencing of ...... androgen-deprivation therapy.

@en

P2093

David Sims

http://www.w3.org/2001/XMLSchema#string

Ernest Mui

http://www.w3.org/2001/XMLSchema#string

Ian D Pedley

http://www.w3.org/2001/XMLSchema#string

Janis Fleming

http://www.w3.org/2001/XMLSchema#string

M Eugenia M Villasevil

http://www.w3.org/2001/XMLSchema#string

Mark Davis

http://www.w3.org/2001/XMLSchema#string

Rhona M McMenemin

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

The beta-catenin binding protein ICAT modulates androgen receptor activity

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays

The KEGG resource for deciphering the genome

Wnt/β-catenin signalling in prostate cancer

Integrins in cancer: biological implications and therapeutic opportunities

The mutational landscape of lethal castration-resistant prostate cancer

The development of androgen-independent prostate cancer

P304

32-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.08.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

Prabhakar Rajan

P577

2013-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256928638

http://www.w3.org/2001/XMLSchema#string

P698

24054872

http://www.w3.org/2001/XMLSchema#string

P921

P932

4062940

http://www.w3.org/2001/XMLSchema#string